Every peptide page carries a tier badge that reflects the strength of the underlying human evidence — not the confidence of the supplier marketing it.
FDA-approved for at least one indication, with supporting phase 3 randomized controlled trials. Strong human evidence, published in major journals, regulatory review completed.
EX · Semaglutide, Tirzepatide, Tesamorelin, Liraglutide, Teriparatide
Phase 1–2 human data published, or approved in non-US jurisdictions with Western clinical literature. Real human safety and efficacy signal exists, but trials are small, approvals are non-US, or confirmatory phase-3 work is missing.
EX · Cerebrolysin, Thymosin Alpha-1, TB-500 (ophthalmic Phase II), Retatrutide
Animal studies only. Limited or no human data. Preclinical findings can be extensive — but extrapolating to humans is speculative, especially when the evidence comes from a single laboratory. Single-lab dominance is flagged on every Tier 3 page it applies to.
EX · BPC-157, MK-677 (halted development), most off-label GH secretagogues
Cell culture studies, mechanistic hypotheses, or isolated in-vitro claims. Compelling ideas with very thin empirical backing, often dominated by a single research group without independent replication. Treat all claims with skepticism.
EX · Dihexa, Epitalon (telomerase activity claims), FOXO4-DRI